A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is evaluating the impact a collaborative palliative care and oncology team will have on the quality of life, symptoms, mood, and end of life outcomes of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

NCT03310918

Acute Myeloid Leukemia Myelodysplastic Syndromes

ACTIVE_NOT_RECRUITING NA

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

NCT04482894

Leukemia, Acute AML, Adult ALL, Adult +1 more

ACTIVE_NOT_RECRUITING PHASE2

Enhanced Palliative Care in MDS and AML

NCT04226768

Myelodysplastic Syndromes

UNKNOWN NA

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

NCT05237258

Relapsed Adult AML Primary Refractory Acute Myeloid Leukemia High Risk Acute Myeloid Leukemia

RECRUITING NA

Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

NCT00525746

Leukemia Myelodysplastic Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main purpose of this study is to compare two types of care - standard leukemia oncology care and standard leukemia oncology care with collaborative involvement of palliative care clinicians to see which is better for improving the experience of patients and families with AML and MDS undergoing treatment.

The investigators aim to find out whether introducing patients and families undergoing AML and MDS treatment to the palliative care team that specializes in symptom management can improve the physical and psychological symptoms that patients and families experience during their hospitalizations for their leukemia care as well as enhance the quality of patients' end of life care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Leukemia Care

Standard Leukemia care

Group Type ACTIVE_COMPARATOR

Standard Leukemia Care

Intervention Type OTHER

Collaborative Palliative and Oncology Care

Collaborative care from Palliative Care and Leukemia will be given

Group Type EXPERIMENTAL

Palliative Care

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Leukemia Care

Intervention Type OTHER

Palliative Care

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients with high-risk AML, defined as:
* Newly diagnosed patients with AML ≥ 60 years of age
* Newly diagnosed AML with antecedent hematologic disorder
* Newly diagnosed therapy-related AML
* Relapsed AML
* Primary refractory AML

Exclusion Criteria

* Patients already receiving palliative care
* Major psychiatric illness or comorbid conditions prohibiting compliance with study procedures.
* A diagnosis of acute promyelocytic leukemia (APML)

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No